Kidney Cancer Care
Kidney Cancer (Renal Cell Carcinoma) in Secunderabad — Early Detection, Robotic Surgery, Kidney Preserved Where Possible
At a glance
Condition
Kidney Cancer — Renal Cell Carcinoma (RCC). Also: Transitional Cell Carcinoma (TCC) of renal pelvis.
How most cases are found
Incidentally — during an ultrasound or CT scan done for an unrelated reason. Most patients have no symptoms at diagnosis.
★ Most important fact
Early-stage kidney cancer (Stage I–II, confined to the kidney) is highly curable with surgery. 5-year survival for Stage I: over 90%.
★ Treatment & Decision Pathway
Most kidney cancers can be treated effectively, with a strong emphasis on preserving kidney function wherever possible.
Preferred surgery — small tumours
Robotic Partial Nephrectomy — removes only the tumour, preserves the healthy kidney. Da Vinci Xi & X at KIMS.
Surgery for large tumours
Robotic Radical Nephrectomy — removes the whole kidney when partial resection is not feasible.
Every case reviewed by
Multidisciplinary Tumour Board at KIMS — urological surgeon, medical oncologist, radiation oncologist, radiologist.
For advanced/metastatic disease
Targeted therapy (TKIs, mTOR inhibitors), immunotherapy (checkpoint inhibitors) — coordinated at KIMS with medical oncology.
Appointments
040 - 44885000 · assistance@kimshospitals.com
What is kidney cancer?
Kidney cancer begins when cells in the kidney start to grow and divide abnormally, forming a tumour. The most common type accounting for approximately 85% of kidney cancers in adults is Renal Cell Carcinoma (RCC), which originates in the lining of the small tubules within the kidney. Clear cell RCC is the most frequent subtype, with papillary and chromophobe RCC making up most of the remainder.
Transitional Cell Carcinoma (TCC) of the renal pelvis accounts for approximately 8% of kidney cancers originating not in the kidney cells themselves but in the lining of the renal pelvis, the collecting area where urine drains into the ureter. TCC behaves differently from RCC and has a high risk of recurrence in the urinary tract.
Kidney cancer is staged from I to IV based on tumour size and extent of spread. Stage I (tumour confined to kidney, 7cm or less) carries an excellent prognosis with surgical treatment. Stage IV (spread to distant organs) requires a combination of surgery and systemic therapy. Accurate staging determines everything which operation, whether the kidney can be preserved, and whether additional treatment beyond surgery is needed.
Symptoms — why most kidney cancers have none
Kidney cancer is often called a 'silent tumour' because the kidneys sit deep in the retroperitoneum — the space behind the abdominal organs — where a tumour can grow for years without causing noticeable symptoms. When symptoms do appear, they typically indicate a tumour that has grown significantly.
Visible blood in the urine — even once, even painless — always requires investigation. At KIMS, haematuria is evaluated with urine microscopy, imaging (CT KUB), and cystoscopy to identify the source. Do not wait to see if it resolves on its own.
Blood in the urine (haematuria) — visible blood makes urine appear pink, red, or tea-coloured. May be intermittent and painless
A lump or mass felt in the flank or abdomen — usually indicates a large tumour
Persistent pain in the flank or back — not related to a kidney stone or urinary infection
Unexplained weight loss and loss of appetite
Persistent fatigue and anaemia — due to tumour-related hormonal effects
Fever without apparent infection — caused by tumour-related cytokines
High blood pressure that is new or suddenly difficult to control — some tumours produce renin
Kidney cancer staging — what the stage means for treatment
| Stage | What it means | 5-year survival (RCC) | KIMS approach |
|---|---|---|---|
| Stage I | Tumour 7cm or less, confined to kidney | 90%+ with surgery | Robotic partial nephrectomy (remove tumour, preserve kidney). Day surgery or 1–2 nights. |
| Stage II | Tumour over 7cm but still confined to kidney | 75–80% with surgery | Robotic partial or radical nephrectomy depending on tumour size and position. Tumour board review. |
| Stage III | Tumour invades renal vein, IVC, or one lymph node — but not spread beyond | 50–60% with surgery | Robotic or open radical nephrectomy. IVC thrombectomy for venous involvement. Medical oncology review. |
| Stage IV | Spread to adrenal gland (beyond), multiple lymph nodes, or distant organs | 10–15% (5-year) | Surgery where feasible (cytoreductive nephrectomy) + systemic therapy: TKI targeted therapy or immunotherapy (checkpoint inhibitors). Multidisciplinary approach. |
These survival figures are from published international data for renal cell carcinoma. They represent population-level outcomes and not individual predictions. At KIMS, every case is assessed individually by the tumour board before any prognosis is discussed.
How kidney cancer is diagnosed at KIMS
If a kidney mass is found on ultrasound or incidentally during another investigation, the next step at KIMS is a dedicated contrast-enhanced CT scan of the abdomen and pelvis (the gold standard for characterising renal masses) and a CT chest (to check for pulmonary metastases). For equivocal masses where the CT cannot definitively distinguish benign from malignant, an MRI of the kidney or a CT-guided renal mass biopsy may be performed.
Blood and urine tests include a full metabolic panel (kidney function, liver function, calcium, haemoglobin), urine microscopy, and urinalysis. A bone scan or CT of the head is added if there are symptoms suggesting bone or brain involvement.
Once staging is complete, the case is presented at the KIMS multidisciplinary tumour board before any treatment plan is discussed with the patient.
Kidney cancer treatment at KIMS — the multidisciplinary approach
The treatment of kidney cancer depends on the stage, the tumour size and position within the kidney, the function of the opposite kidney, and the patient's overall health. Every case at KIMS is reviewed by the tumour board before treatment is recommended — no single-specialist decision-making.
Robotic Partial Nephrectomy — the gold standard for most kidney cancers
For Stage I kidney cancer — tumours 7cm or less confined to the kidney — robotic partial nephrectomy (removing the tumour with a clear margin of healthy tissue, preserving the rest of the kidney) is the internationally recommended standard of care. KIMS performs this with Da Vinci Xi and X robotic systems — the most advanced available. Partial nephrectomy was once performed only for specific patients (single kidney, impaired opposite kidney, bilateral tumours). Today, for tumours under 7cm, it is the preferred approach for all suitable patients — because preserving kidney tissue directly reduces the long-term risk of CKD, cardiovascular disease, and mortality that accompany a permanently reduced kidney mass. Best for: Stage I–II tumours up to 7cm in most anatomical positions What is removed: The tumour plus a clear margin of healthy tissue — the rest of the kidney is preserved Approach: Da Vinci Xi or X robotic surgery — 3–5 keyhole ports, 3D magnified view, sub-mm precision Incision: No large incision — 3–5 small ports (5–8mm each) Blood loss: Significantly less than open surgery Warm ischaemia time: KIMS surgeons aim to keep the kidney unclamped (zero ischaemia) or minimise clamping time — protecting remaining kidney function Hospital stay: 1–3 nights Return to work: 2–3 weeks for desk work Tissue specimen: Sent to pathology for full histological analysis — confirms diagnosis, subtype, surgical margin status
Robotic Radical Nephrectomy — when the whole kidney must be removed
Radical nephrectomy — removal of the entire kidney along with surrounding fat, and sometimes the ipsilateral adrenal gland and nearby lymph nodes — is performed when: the tumour is too large or positioned such that partial resection cannot achieve clear margins, the tumour involves the renal vein or IVC (requiring vascular reconstruction), or when the contralateral kidney is fully functional and partial resection is not technically feasible. At KIMS, radical nephrectomy is performed robotically using Da Vinci Xi and X for most cases — through 3–5 keyhole ports without a large flank incision. Open radical nephrectomy is performed for very large tumours, IVC thrombus requiring extensive vascular surgery, or complex reoperative anatomy. Every patient undergoing radical nephrectomy at KIMS has their contralateral kidney function assessed and documented before surgery, and post-operative nephrology follow-up is arranged.
Active Surveillance — for small, low-risk tumours in selected patients
For small renal masses under 2cm, or for elderly patients or those with significant comorbidities where surgery carries elevated risk, active surveillance — regular imaging (CT or MRI) to monitor growth — is a medically validated alternative to immediate surgery. The KIMS tumour board reviews all surveillance candidates individually. If a tumour grows beyond 3–4cm or shows growth rate exceeding 5mm per year, surgical intervention is recommended.
Systemic therapy for advanced and metastatic kidney cancer
Stage IV kidney cancer — spread beyond the kidney to distant organs — is managed with systemic therapy, often combined with surgery (cytoreductive nephrectomy) in selected patients. At KIMS, every advanced kidney cancer case is reviewed by both the uro-oncology surgical team and the medical oncologist to plan the most effective combination approach. Targeted therapy (TKIs): Tyrosine kinase inhibitors — sunitinib, pazopanib, axitinib, cabozantinib — block the blood vessel growth signals that RCC tumours depend on. These are taken orally and can significantly control tumour growth in metastatic RCC. Immunotherapy (checkpoint inhibitors): Nivolumab, pembrolizumab, and combination regimens (nivolumab + ipilimumab, pembrolizumab + axitinib) activate the immune system to recognise and attack RCC cells. Immunotherapy combinations are now first-line for most advanced RCC patients. KIMS medical oncology coordinates and monitors these treatments.
Why choose KIMS Secunderabad for kidney cancer treatment?
KIMS provides comprehensive kidney cancer care — from diagnosis to robotic surgery and advanced systemic therapy — delivered through a coordinated multidisciplinary approach.
Multidisciplinary tumour board decision-making
Every kidney cancer case at KIMS is reviewed by a multidisciplinary tumour board — including the urological oncologist, medical oncologist, radiation oncologist, and radiologist — before any treatment decision is made. This ensures evidence-based, consensus-driven care rather than single-specialist decision-making.
Da Vinci Xi & X robotic systems
KIMS operates both Da Vinci Xi and X robotic platforms — enabling highly precise partial nephrectomy. With 10x magnified 3D vision and sub-millimetre instrument control, surgeons can remove tumours completely while preserving maximum healthy kidney tissue.
Kidney preservation as a priority
For most early-stage kidney cancers, KIMS prioritises robotic partial nephrectomy — removing only the tumour while preserving the rest of the kidney. This reduces long-term risks of chronic kidney disease, cardiovascular complications, and mortality.
Integrated oncology care on one campus
For advanced kidney cancer, uro-oncology surgery, medical oncology, and radiation oncology are all available within the same 1,000-bed KIMS campus — ensuring seamless coordination of surgery, targeted therapy, and immunotherapy.
Advanced systemic therapy expertise
KIMS provides targeted therapy (TKIs) and immunotherapy (checkpoint inhibitors) for advanced and metastatic kidney cancer, with treatment plans coordinated and monitored by dedicated medical oncology specialists.
Nephrology follow-up after surgery
After partial or radical nephrectomy, patients are followed by the KIMS nephrology team to protect long-term kidney function — including monitoring kidney parameters, controlling blood pressure, and avoiding nephrotoxic medications.
Start Kidney Failure Care at KIMS
Our kidney cancer specialists at KIMS Secunderabad
Our uro-oncology team specialises in kidney cancer surgery, including robotic partial and radical nephrectomy, with a strong focus on kidney preservation and minimally invasive techniques.
Frequently Asked Questions
Not necessarily — but it must be investigated urgently. Most kidney masses discovered on scan are malignant (approximately 75–80%), but some are benign — simple cysts, angiomyolipomas (fatty tumours), oncocytomas. The distinction is made with a contrast-enhanced CT scan at KIMS. If the CT shows features highly suspicious for malignancy, no biopsy is usually needed before surgery — the diagnostic accuracy of modern CT for renal masses is very high. If there is genuine uncertainty between benign and malignant (particularly for small masses), a CT-guided renal mass biopsy may be performed. Do not wait to investigate a kidney mass, even if you feel completely well.
Not necessarily — and for most small kidney cancers, the answer is no. For Stage I kidney cancers (tumours 7cm or less confined to the kidney), robotic partial nephrectomy — removing only the tumour with a clear margin, preserving the rest of the kidney — is the internationally recommended standard of care. KIMS performs robotic partial nephrectomy using Da Vinci Xi and X systems. The goal is always to remove the cancer completely and keep as much healthy kidney tissue as possible, because preserving kidney function reduces long-term CKD risk significantly.
Yes — particularly when found early. Stage I kidney cancer (tumour confined to the kidney, 7cm or less) has a 5-year survival rate exceeding 90% with surgical treatment. Stage II has approximately 75–80% 5-year survival. Even Stage III — where the tumour has grown locally or involved the renal vein — has a 50–60% 5-year survival with surgery. Advanced Stage IV kidney cancer (spread to distant organs) has a lower survival rate but has been significantly improved by modern targeted therapy and immunotherapy combinations. The most important variable is stage at detection — which is why incidental early detection through ultrasound is so valuable.
Robotic partial nephrectomy uses Da Vinci robotic systems (Xi and X at KIMS) to remove a kidney tumour through 3–5 small keyhole ports — with a 10x magnified 3D view that allows the surgeon to excise the tumour with precision while preserving the surrounding healthy kidney tissue. It is preferred over radical nephrectomy (removing the whole kidney) for tumours under 7cm because: it removes the cancer with equivalent cure rates to radical nephrectomy for Stage I disease, preserves kidney function (reducing long-term CKD, cardiovascular disease, and mortality risk), has less blood loss and faster recovery than open surgery, and most patients are discharged within 1–3 nights.
A multidisciplinary tumour board (MDT) is a meeting of specialists from different fields — urological surgeon, medical oncologist, radiation oncologist, and radiologist — who review each cancer case together before a treatment plan is recommended. Evidence shows that MDT review improves treatment decisions and patient outcomes for urological cancers. Yes — every kidney cancer case at KIMS is presented at the multidisciplinary tumour board before any treatment discussion with the patient. No unilateral surgical decisions are made without MDT review.
Stage IV kidney cancer that has spread to distant organs is managed with systemic therapy — medication that acts throughout the body rather than surgery alone. Modern treatment typically involves combinations of targeted therapy (tyrosine kinase inhibitors such as sunitinib, pazopanib, or axitinib) and immunotherapy (checkpoint inhibitors such as nivolumab or pembrolizumab). Combination regimens — particularly nivolumab + ipilimumab and pembrolizumab + axitinib — are now first-line for most patients with advanced RCC. In selected patients, surgery to remove the primary kidney tumour (cytoreductive nephrectomy) before or alongside systemic therapy improves outcomes. At KIMS, advanced kidney cancer is managed jointly by the uro-oncology surgical team and the medical oncology department within the same campus.
After robotic partial nephrectomy at KIMS: hospital stay is typically 1–3 nights. Most patients with desk jobs return to work within 2–3 weeks. Physical activity and heavy lifting should be avoided for 4–6 weeks. A follow-up CT scan at 3 months confirms complete tumour removal and monitors the preserved kidney tissue. After robotic radical nephrectomy: hospital stay is 2–3 nights. Return to desk work: 2–4 weeks. Full recovery: 4–6 weeks. Long-term monitoring includes annual kidney function blood tests — particularly important after radical nephrectomy where one kidney must compensate for the loss.
KIMS Secunderabad's Uro-Oncology team treats kidney cancer at every stage — from small incidental tumours managed with robotic partial nephrectomy (preserving the kidney) through advanced disease requiring systemic therapy and complex surgery. Every case is reviewed by a multidisciplinary tumour board before treatment is planned. KIMS operates Da Vinci Xi and X robotic systems for the most precise minimally invasive surgery. Medical oncology and radiation oncology are available within the same 1,000-bed campus for advanced cases. KIMS is NABH accredited and empanelled under Aarogyasri, CGHS, and major private insurance.